Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $42.75.

A number of brokerages recently weighed in on ASMB. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Guggenheim lifted their price objective on shares of Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 6th. Finally, Wall Street Zen upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ASMB. Acadian Asset Management LLC grew its holdings in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 3,312 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in shares of Assembly Biosciences in the third quarter valued at approximately $852,000. Vanguard Group Inc. grew its holdings in shares of Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares in the last quarter. Finally, Patient Square Capital LP acquired a new position in shares of Assembly Biosciences in the third quarter valued at approximately $3,461,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of ASMB opened at $28.42 on Friday. Assembly Biosciences has a 1-year low of $8.15 and a 1-year high of $39.71. The stock has a market cap of $450.74 million, a PE ratio of -38.40 and a beta of 1.15. The firm has a 50-day simple moving average of $28.25 and a two-hundred day simple moving average of $30.21.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. The business had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $7.42 million. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. As a group, sell-side analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.